On 1 May 2025, Haleon CEO, Brian McNamara, and other members of the Executive Leadership Team hosted a Capital Markets Day in London which was broadcast online.
The agenda covered progress we have made over the last three years since listing Haleon on the London and New York stock exchanges and outlined our Win as One strategy as we move into the next chapter of our growth journey.
Scroll down to access the presentations, transcripts, press release, and other supplementary information.
Our Win as One strategy will allow us to capitalise on the significant opportunity ahead, through a sharpened focus on driving penetration across our resilient and growing categories, alongside significant productivity gains through optimising our supply chain.
APAC
Oral Health category
Pain Relief category
India case study
| Haleon Capital Markets Day Agenda | Time (approximately) |
| Unlocking our full potential | 13:00 BST |
| Brian McNamara CEO |
|
| Driving category growth through Superior Brands | 13:25 BST |
Tamara Rogers Franck Riot |
|
| Winning in Pharmacy | 13:55 BST |
| Filippo Lanzi President, EMEA and LATAM |
|
| Breakout Sessions (live in room) | 14:25 BST |
Oral Health - US Pain Relief – Italy, Pakistan, Brazil Vitamins, Minerals and Supplements (VMS) – China, Philippines |
|
| Optimising our Supply Chain | 15:30 BST |
| Namrata Patel Chief Supply Chain Officer |
|
| Value Creation Framework | 16:10 BST |
| Dawn Allen Chief Financial Officer |
|
| Q&A | 16:40 BST |
Brian is the CEO of Haleon, having been appointed in July 2021.
Prior to that, he had led the Consumer Healthcare business since 2016, while it was still part of GSK. He is focused on shaping a strategy for growth that puts purpose at its heart. He leads 23,000 employees across more than 100 countries, who are working every day to deliver better everyday health with humanity. Brian initially joined GSK Consumer Healthcare as Head of Europe and the Americas in 2015.
Previously, he spent three years as the Over-the-Counter (OTC) Division Head at Novartis and a member of the Novartis Executive Committee, following a number of senior leadership roles across his ten-year tenure at the company.
Dawn Allen assumed her role as Chief Financial Officer and Board member of Haleon in November 2024.
Dawn is a Chartered Accountant, with an extensive and proven track record of financial, international and consumer experience. She joins Haleon from Tate & Lyle plc where she was CFO and member of the Board and Executive Team.
Her previous experience includes a 25-year career at Mars Inc. where she was more recently Global CFO and Vice President of Global Transformation.
Namrata was appointed Chief Supply Chain Officer in November 2023. Namrata joined Haleon from Procter & Gamble, where she spent 17 years in various leadership roles.
Tamara was appointed Chief Marketing Officer in 2019, while the business was still part of GSK, having previously served as Region Head for EMEA. Prior to joining GSK, Tamara spent nearly 25 years at Unilever, having joined as a Management Trainee in the UK.
Franck was appointed Head of Global R&D in 2019, while the business was still part of GSK. Previously, Franck was Vice President of Research and Innovation at Danone for the Essential Dairy and Plant-Based World-Wide Business Unit from 2017-2019.
Namrata was appointed Chief Supply Chain Officer in November 2023. Namrata joined Haleon from Procter & Gamble, where she spent 17 years in various leadership roles.
Keith was appointed Head of Asia Pacific in 2019, while the business was still part of GSK. Before joining GSK, Keith was the President for International markets of Pfizer Consumer Healthcare (PCH). He previously served as the Regional President of APAC PCH and before that as China GM, where he oversaw significant sales growth in the China OTC category.
Filippo was appointed Head of EMEA and Latin America for Haleon in 2021, having previously served as EMEA Lead from 2019, while the business was still part of GSK. Prior to joining GSK, he was the Operating Unit Head in Italy and Greece for Novartis’ OTC business.
Related
